



















Less (mTOR signaling) is More (lifespan) 
 
Further expanding the major findings of the landmark 
study by Harrison and colleagues showing that late-life 
pharmacological inhibition of the enzyme mammalian 
Target Of Rapamycin (mTOR) –a conserved integrator 
of nutrient and growth factor signaling- is sufficient to 
significantly extend lifespan in mice on rapamycin 
feeding [1], Selman and colleagues have recently 
revealed that loss of the ribosomal S6 protein kinase 
S6K1 –a downstream target and effector of mTOR- can 
similarly provide health and longevity effects without 
detrimental effects when targeted pharmacologically 
[2]. As previously observed in calorie restriction (CR)-
related interventions that similarly delayed aging in 
Caenorhabditis elegans, rodents and rhesus monkeys 
[3], long-lived S6K1 knockout animals exhibit a 
reduced body size [2]. Pro-longevity features in animals 
lacking S6K1, including hyperactivation of the 
metabolic rheostat adenosine monophosphate (AMP)-
activated protein kinase (AMPK) and transcriptional 
alterations of key genes involved in the regulation of 
glucose and lipid metabolism, paradoxically imitate 
those observed in reliable models of human progeria in 
which certain aspects of aging are manifested 
precociously or in exacerbated form [4]. We have 
learned that, in their attempt to re-allocate resources 
from growth to life extension, rapidly aging progeroid 
mice with nuclear envelope abnormalities –which could 
also be a central cause of normal aging- metabolically 
adopt CR-like strategies (i.e. activation of AMPK and 
inhibition of mTOR/S6K1 leading to extensive 
activation  of  autophagic  catabolism)  aimed  to         
slow-down cellular division-dependent accumulation  of  
 
 



















genomic damage [5]. While it is obvious that systemic 
CR-like metabolic responses fail to repair nuclear 
architecture defects and rather accelerate death in 
progeroid mice, it is also obvious that, upon activation 
of AMPK in animals lacking S6K1, CR-like metabolic 
responses successfully accomplish an anti-aging 
mechanism while significantly decreasing body size [2].  
 
Less (AMPK-sensed anabolism) is More (lifespan)  
 
If activation of AMPK (and/or inhibition of 
mTOR/S6K1) constitutes the best metabolic response to 
avoid that a normal growth rate would compromise 
somatic integrity in progeroid animals [4, 5], it is 
reasonable to suggest that the occurrence of AMPK 
upregulation upon loss of S6K1 would lead also to 
reductions in cell growth/division rates in order to avoid 
that bioenergetic stresses might trigger cell death. In 
this regard, we should acknowledge that metabolic 
requirements are identical in all proliferating (normal, 
cancer, and stem) cells and, proliferative metabolism is 
successfully adapted in all of them to facilitate and 
ensure the rapid uptake and efficient incorporation of 
nutrients into the biomass needed to produce new cell 
progeny [6]. An intuitive function of evolutionary 
conserved low-energy checkpoints such as the 
AMPK/mTOR/S6K1 longevity pathway is therefore to 
suppress cell proliferation by preventing nutrient 
utilization for anabolic processes [7, 8]. Unfortunately, 
it remains to be elucidated to which extent the 
interaction between the (AMPK-regulated) energy 
sensing and the (mTOR-regulated) sensing of signals 
arising from insulin, IGF-1, and amino-acids can 
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Moreover, the well-recognized ability of CR-induced 
deactivation of the mTOR pathway to slow growth, 
fitness and the onset of reproduction [10-12] while 
reducing risk of cancer (i.e. “preventing cancer by 
inhibiting aging” [13-15]) remains to be understood in 
terms of stem-cell contribution to homeostasis & repair 
in tissues with different degrees of cellular turnover and 
regenerative potential [9]. Although we know that anti-
aging interventions started in younger animals appear to 
be more effective in terms of lifespan extension when 
compared to these interventions initiated in late middle 
or old age, a practical question that remains unanswered 
is: If started early in life, could CR-like interventions 
efficiently increase lifespan without interfering normal 
ontogenetic development? 
 
Even if findings from Colman and colleagues 
demonstrating significant lifespan extension in rhesus 
monkeys can definitely substantiate CR as an effective 
pro-longevity strategy for humans [16], many people 
would prefer the effortlessness and perceived 
confidence of being treated with CR-Mimetic (CRM) 
pills. These CRMs are expected to reproduce some or 
all of the life- and health span-extending effects of CR 
including reduced incidence and delayed onset of age-
related diseases such as cancer [17-20]. This new 
research on CRMs, therefore, aim to create or identify 
compounds that mimic CR effects by targeting 
metabolic (e.g. the glycolysis inhibitor 2-deoxyglucose) 
and stress response pathways (e.g. the sirtuin activator 
resveratrol) affected by CR, but without actually 
restricting caloric intake. Because promising results 
begin to emerge from initial studies regarding 
physiological responses which resemble those observed 
in CR (e.g. reduced plasma insulin), the insulin-
sensitizing biguanide metformin begins to be catalogued 
as a CRM more than fifteen years after its launch for the 
treatment of type 2 diabetes. In vitro studies have 
suggested that metformin might molecularly 
recapitulate most of the pro-longevity effects occurring 
upon loss of S6K1. Metformin exposure efficiently 
suppresses S6K1 activity in cultured proliferating 
epithelial cells [21-23]. Despite overall reduction in 
global mRNA translation in response to metformin-
induced dephosphorylation of S6K1 [24], metformin 
treatment triggers a complex transcriptional program 
that includes up-regulation of genes coding for several 
aminoacyl-tRNA synthetases and RNA helicases [25], 
which might account for yet to be determined 
metformin-regulated mechanisms of differential 
translation with respect to specific mRNAs. A similar 
mechanism has been suggested by Selman and 
colleagues to explain the occurrence of AMPK protein 
upregulation upon loss of S6K1 [2]. If long-term 
exposure to the AMPK agonist metformin might 
activate a S6K1/AMPK auto-regulatory feed-back loop 
certainly merits to be investigated. Metformin treatment 
further affects the human transcriptome to modulate 
numerous genes coding for mitotic checkpoint proteins 
such as BubR1, which have also been reported to 
significantly impact on aging [26-28].  
 
Less (epithelial-to-mesenchymal transition) is More 
(somatic cell identity)  
 
Metformin treatment has been recently found to 
selectively target tumor-initiating cancer stem cells 
(CSCs) in breast cancer cell cultures [29-31], likely 
mimicking a yet to be explored pro-longevity ability of 
metabolic stress-induced activation of AMPK [32]. On 
the one hand, a recently described transcriptional 
roadmap to the establishment of induced pluripotent 
stem (iPS) cells derived from somatic cells has revealed 
that induction of ground state pluripotency is favored by 
the inhibition of Epithelial-to-Mesenchymal Transition 
(EMT) and hence the induction of the reverse process, 
the Mesenchymal-to-Epithelial Transition (MET) [33]. 
On the other hand, during cell division, one of the major 
features of somatic cell reprogramming by defined 
factors, cells are potentially exposed to DNA damage. 
Inactivation of the Ataxia-telangiectasia mutated 
(ATM), which is critical in the cellular response to 
DNA double-strand breaks, has been recently shown to 
decrease reprogramming efficiency and leads to 
genomic instability in iPS cells [34]. Metformin 
treatment might directly impede the ontogeny of 
generating the CSC phenotype by repressing the stem 
cell property EMT [35-38]. Metformin treatment has 
been shown to transcriptional inhibit the expression of 
the pivotal inducer & drivers of the EMT machinery 
TGFs, Zeb, Twist and Slug [35, 36]. Metformin 
treatment prevents conversion of epithelial into 
migratory mesenchymal cells by molecularly helping 
cancer cells to keep in their differentiated epithelial 
state [37]. Metformin’s ability to enhance the epithelial 
behavior of cancer cells not only may occur through 
transcriptional inhibition of the “E-cadherin repressor 
interactome” (thus enhancing the expression of the 
metastasis suppressor protein E-cadherin at cell-cell 
junctions) but also by epigenetically preserving the 
differentiated phenotype of human epithelia via up-
regulation of the microRNA let-7a [38], a crucial 
regulator of CSC maintenance and point at connection 
between EMT and CSC formation [39]. Moreover, a 
previously unrecognized cancer chemopreventive 
activity of metformin (i.e. metformin’s ability to cause 
pre-malignant lesions to recede or disappear thus 
preventing or delaying the onset of invasive cancer) 
may relate to metformin’s ability to unexpectedly up-
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cells [40-42]. Although there is no conclusive evidence 
that the maximal human lifespan is determined by 
declining stem-cell function or, conversely, that 
increasing the number of functionality of any single 
stem-cell population would extend lifespan, it would be 
relevant to evaluate whether metformin-activated CR-
like molecular responses may raise reprogramming 
efficiency without increasing number of abnormal 
chromosomes during establishment of iPS cells. Given 
that EMT/MET and DNA-damage responses are typical 
events of development, tissue repair and tumor 
progression and considering the potential of iPS cells as 
a useful tool for elucidating the molecular mechanism 
of cell aging, forthcoming studies should clarify if 
metformin-induced repression of the mesenchymal 
program may actively regulate reprogramming of 
somatic cell identity, thus contributing to stem cell-
related tissue homeostasis & repair (at least in tissues 
with high regenerative potential).  
 
Less (age at starting metformin treatment) is More 
(lifespan) 
 
Translation of in vitro results into in vivo applications 
may significantly alter, however, the assumed CRM 
nature of the biguanide metformin. A recent study by 
Anisimov and colleagues published in a previous issue 
of Aging (Albany NY) may certainly establish that 
metformin should be defined as geroprotective or 
gerosuppressant rather than bona fide CRM. Long-
living female mice from the outbred SHR strain were 
fed metformin in drinking water beginning at 3, 9 or 15 
months of age and they were then analyzed for 
reproductive aging, mean & maximal lifespan and 
incidence of malignant tumors [43]. Metformin’s effects 
on the reproductive function of SHR mice largely 
recapitulated metformin’s ovulatory effects in women. 
Metformin is known to delay premature onset of the 
menstrual cycle in girls while restoring ovulations in 
women with premature menopause [44, 45]. Similarly, 
metformin treatment of SHR mice significantly 
improved reproductive function measured as a 
statistically significant increase in both the rate of SHR 
mice exhibiting shorter length of estrous cycles and the 
fraction of SHR mice with regular cycles. Prevention of 
reproductive aging (i.e. degeneration of the estrous 
cycle) occurred when metformin treatment was started 
at any age. These findings are consistent with a scenario 
in which a/the genetically-programmed function 
targeted by metformin (e.g. the mTOR pathway) is to 
drive reproduction because it was efficiently activated 
in an age-independent manner.  
 
Earlier studies from the same group showed that 
metformin treatment increased mean lifespan of SHR 
mice by >37% and increased maximum lifespan by >10 
months [46]. Metformin was found to extend the mean 
lifespan of the longest-living animals (i.e. the last 10% 
of survivors in the study population) by >20% and, in 
tumor-free mice, metformin treatment impressively 
extended the mean lifespan by ~70% (from 290 to 494 
days). The incidences of the primary types of 
spontaneous malignant tumors in SHR mice (i.e. 
mammary carcinomas and leukemias), however, were 
not significantly affected by metformin feeding [46]. In 
their latest study, Anisimov and colleagues provide 
evidence that metformin fed late in life failed to extend 
lifespan in 15 month-old female SHR mice. Indeed, 
metfomin’s ability to increase lifespan augments from 
an insignificant 6% when metformin treatment was 
initiated at the middle-age of 9 months up to 14% when 
metformin treatment was initiated early in life (i.e. at 
the young age of 3 months) [43]. In agreement with 
earlier findings in SHR mice [46], metformin treatment 
postponed detection of the first tumor by >20% when 
metformin feeding was initiated early and in the middle 
age; metformin treatment, however, failed to decrease 
total tumor incidence. In transgenic female mice (strain 
FVB/N) carrying a neu oncogene, which predispose 
animals to mammary cancer, the same group showed 
that metformin treatment modestly extended the 
lifespan by 8% and simultaneously delayed cancer onset 
and decreased cancer incidence & multiplicity [47, 48]. 
In female SHR mice, Anisimov and colleagues now 
confirm that metformin treatment, if started early in life, 
notably increases by 21% the mean lifespan of tumor-
free mice [43]. In contrast, if started late in life, 
metformin treatment appears to significantly reduce (by 
13%) the mean lifespan of tumor-free mice. These 
findings do not appear to support earlier suggestions 
that metformin might be better administered late in life 
to minimize early life metformin pleiotropic effects 
[e.g. metformin selected reservoir of malignancy-prone 
cells hypersensitive to selection of IGF-I signaling; 49-
51]. It is perhaps relevant to note that, if started early in 
life, metformin treatment decreased the risk of death 
compared to the control group whereas similar 
treatment with metformin at older ages did not affect 
the relative risk of death in SHR female mice. 
Metformin’s ability to increase the mean lifespan of 
tumor-free mice while simultaneously decreasing the 
risk of death in an age-related manner somewhat 
recapitulate metformin’s ability to reduce cancer 
incidence among type 2 diabetic individuals. 
Confirming and expanding further a landmark study by 
Evans and colleagues [52],  who originally reported that  
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significantly reduced in patients with type 2 diabetes 
who received metformin and that metformin’s 
protective effect increased with greater metformin use 
(i.e. dose and/or time), a recently conducted 
retrospective study has reported an impressive 56% 
decrease in breast cancer risk among diabetic receiving 
metformin compared with diabetics treated with other 
therapies [53]. Available data reveal also that reductions 
in cancer mortality related to metformin use are similar 
in magnitude to reductions in cancer incidence, thus 
suggesting that metformin’s anti-cancer effects largely 
depend on (or are restricted to) its preventive effects 
[54].  
 
Gerosuppressant metformin: Testing the “less is 
more” minimalist leitmotiv  
 
If metformin both prevents cancer and extends lifespan 
in cancer-prone (e.g. neu-N transgenic mouse model of 
mammary cancer) strains of rodents, metformin’s 
ability to prolong lifespan without affecting cancer in 
non-cancer-prone strain of rodents (e. g. SHR) may 
suggest that metformin can prolong life (and delay 
aging) by mechanisms unrelated to its ability to 
suppress cancer. It may not, however, if this 
discrepancy simply relies with the cellular response that 
oncogenes and tumor suppressors have on the 
phenotype of energetic metabolism. Derived from the 
FVB/N strain, neu-N transgenic mice express the 
nontransforming rat neu cDNA under the control of a 
mammary-specific promoter [55]. As a consequence, 
the mice develop spontaneous mammary 
adenocarcinomas beginning at approximately 125 days, 
with the majority of the mice haboring tumors by 300 
days. This transgenic rodent model therefore resembles 
human breast cancer where neu is overexpressed, not 
mutated. Interestingly, the anabolic enzyme Fatty Acid 
Synthase (FASN) –an AMPK-related metformin’s 
lipogenic target [56,57] - is differentially co-
overexpressed with neu in the mammary epithelium of 
the neu-N female mice. Treatment of neu-N transgenic 
mice with the semi-synthetic inhibitor of FASN activity 
C75 has been found to significantly delay mammary 
tumor development (i.e. solely 20% of the C75-treated 
transgenic mice developed mammary carcinoma by 220 
days compared to 50% in the vehicle control animals) 
and complete prevention of the disease in some neu-N 
animals [58]. This chemopreventive effect of the FASN 
inhibitor C75 related to the selective inhibition of both 
mammary duct and lobule development (i.e. C75 
treatment significantly delayed mammary maturation as 
manifested by a reduction of both the number and the 
caliber of mammary ducts and budding epithelial 
structures) restricted to the neu-N transgenic mice. That 
is, pharmacological inhibition of FASN anabolic 
activity had no effect on mammary development in 
wild-type FVB/N mice. The fact that C75’s ability to 
prevent mammary carcinomas via blockade of FASN-
regulated lipogenesis appears to recapitulate 
metformin’s cancer preventive effects in neu-N female 
mice suggests that metformin may have tumor 
suppressing and/or lifespan prolonging effects in 
response to specific metabolic phenotypes (e.g. high 
fuel intake, metabolic syndrome, diabetes and/or 
increased activation of oncogenic signals having similar 
effects on energy metabolism) but may have little or no 
effect at controlling cancer processes driven by energy-
independent molecular events. Indeed, metformin has 
been found to attenuate and reverse the stimulatory 
effect of a high-energy diet on in vivo lung [59], breast 
[60] and colon carcinoma [61] growth, the latter 
occurring via metformin-induced inhibition of FASN 
expression. This complex scenario notably agrees with 
the suggestion that studies on cancer incidence and 
mortality among diabetics in relation to metformin use 
may not have implications for nondiabetics as they do 
not necessarily imply a universal metformin’s 
chemopreventive action [54]. The available population 
studies are retrospective and confined to diabetics, in 
whom risk and prognostic factors that are relatively 
unimportant in the general population may have 
dominant roles [62]. Unfortunately, we are lacking even 
retrospective clinical evidence for antineoplastic 
activity in nondiabetics. Because the ideal cancer 
preventative strategy of the future would employ a 
limited course of low toxicity therapy to suppress pre-
malignant lesions in high-risk cancer patients, 
forthcoming studies should provide a definitive support 
basis concerning clinical application of metformin and 
other biguanides as suppressors of broad-spectrum pre-
malignant lesions. As recently suggested by Pollak [54], 
metformin-based large-scale cancer prevention trials 
would be more justifiable if we could provide criteria to 
specify high-risk populations in which metformin is 
expected to provide a greater benefit. Different 
experimental scenarios may provide crucial insights into 
metformin’s ability to regulate the aging/cancer cross-
paths:  
 
1. Metformin and pre-malignant lesions 
 
Less (life-threatening invasive cancer) is More 
(cancer-free lifespan) 
When considering recent studies describing that pre-
malignant intraepithelial neoplasias such as ductal 
carcinoma in situ (DCIS) of the breast do contain pre-
existing carcinoma precursor cells [63, 64], it would be 
of interest to evaluate whether metformin use in non-
diabetic women might reduce the expected progression 
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threatening invasive breast cancer. In women over 40 
years who did not have known breast cancer during life, 
the median prevalence of invasive breast cancer at death 
was 1.3% and the median prevalence of pre-invasive 
DCIS lesions was 8.9% in autopsy data [65]. These 
findings, together with the ability of progestins to 
reactivate CSCs in pre-existing breast carcinoma 
lesions, may explain why hormone replacement 
therapies significantly increase breast cancer risk in 
some women [66]. This metformin targetable reservoir 
of undetected, pre-invasive breast cancer lesions (or 
dormant CSCs within DCIS) could also underlie the 
apparent implausibility of increased breast cancer risk 
within 2 years among diabetic women receiving the 
insulin analogue glargine [67-69]. That is, hormonal 
factors influencing the natural history of some human 
malignancies including breast cancer (e.g. estrogen, 
insulin, IGF-1) could begin to manifest their effects in 
unexpected short timescales and the observed effects 
(i.e. rapid increase of breast cancer risk) are likely to 
reflect not the initiation of new tumors but rather the 
growth of subclinical malignant lesions to clinically 
diagnosable volumes [70]. Hence it would be 
reasonable to expect metformin to impose a strict 
control of the number and/or proliferation rate of tumor-
initiating progenitors within intraepithelial neoplasias, 
which might be viewed as a very efficient preventive 
mechanism against invasive carcinomas including 
breast cancer in pre- and post-menopausal women. It 
should be noted that, when evaluating either how 
metformin efficacy on tumor growth and metastasis 
related to dietary energy availability or how metformin 
can inhibit the generation and/or maintenance of 
mammary tissue-specific stem cells and their niches, all 
the above mentioned studies observed or assumed that 
metformin treatment was highly effective at suppressing 
systemic metabolic biomarkers such as IGF-1, insulin, 
glucose or estradiol [59-61,71,72]. In Anisimov’s 
experiments, however, metformin treatment was found 
to significantly decrease body temperature when its 
administration started at the age of 3 and 9 months but it 
failed to significantly affect levels of serum cholesterol, 
triglycerides, glucose and insulin. These findings, which 
evidently argue against the notion that metformin is a 
bona fide CRM, may intuitively suggest that metformin 
dose has been insufficient to alter cancer incidence 
despite being sufficient to alter other age-related 
pathologies (thus resulting in “partial” pro-healthy 
effects). It is noteworthy the recent data gained from a 
pilot clinical trial providing evidence that short-term, 
low-dose metformin (250 mg once daily for 1 month 
versus typical 500 mg three times daily in type 2 
diabetes) safely and directly suppresses both colorectal 
epithelial proliferation and aberrant crypt formation 
[73]. Even acknowledged the fact that the 
gastrointestinal tract may be a special case in which 
metformin may act locally from the lumen following 
oral administration [74], we should wondering whether 
one can expect enhanced benefits by achieving more 
continuous exposure by using the slow-release 
metformin preparations developed for dosing 
convenience [75]. Would higher metformin doses 
achieve more impressive effects at increasing life span 
and/or postponing tumors in female SHR mice?   
 
2. Metformin and genetic predisposition to breast 
cancer 
 
Less (endocrine-genotoxic liberation) is More (late 
survival of genetically-driven familial breast cancer) 
It remains to be elucidated how metformin treatment, if 
started early and/or late in life, might significantly 
impact on late-onset diseases, like Alzheimer dementia, 
coronary artery diseases or, perhaps more importantly, 
certain familial forms of cancer. In this regard, an ideal 
scenario relates to genetic susceptibility to breast and 
ovarian cancer in women arising from a mutation in the 
BRCA1 gene, which is one of the most widespread 
genetic diseases [76, 77]. Women with a mutation have 
a 65% risk of developing breast cancer before age 70 
[78]. Breast and ovarian cancers linked to mutations in 
BRCA1 are likely one of the main genetically-related 
causes of death in middle-age women and can be 
therefore regarded as important deleterious mutations in 
old age mortality [79]. Indeed, when all BRCA1 
mutations are taken together, the prevalence of breast 
and ovarian cancer linked to the BRCA1 locus is one of 
the highest among late-onset diseases. Theoretical 
models of aging consider that selection pressures on 
survival at old ages is small (or even null after 
menopause for women) because survival at these ages 
no longer affects fitness. In this scenario, BRCA1 
appears an excellent candidate gene for testing the 
impact of metformin on the theory of evolutionary 
theory of antagonist pleiotropy [80], for which the 
positive selection on alleles associated with increases of 
survival or fertility at young ages must be large enough 
to compensate for non-negligible negative selection on 
survival at old ages. Recent studies have suggested that 
variance in age of onset strongly influences selection of 
alleles involved in susceptibility to late-onset diseases 
that would lead to rapid death of carriers in the absence 
of modern medicine (e.g. breast cancer in BRCA1 
carriers) and that, therefore, alleles under negative 
selection small enough to be traded-off for a positive 
effect at younger ages (e.g. BRCA1) may be more 
strongly negatively selected that thought [79]. Because 
CR itself is antagonistically pleiotropic (i.e. CR slows 
growth, development and reproduction -harmful early in 
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epidemiological and experimental approaches aimed to 
explore the impact of CR, CRMs and gerosuppressants 
such as metformin on the BRCA1-driven complex 
relationship between cancer & aging can be extremely 
informative. We should consider that BRCA1 is a large 
protein with multiple functional domains that interact 
directly or indirectly with a variety of molecules 
through which BRCA1 maintains genome integrity and 
represses tumor formation [81]. On the one hand, 
specific sequences of BRCA1 have been found to play a  
crucial role in longevity because their alteration results 
in the development of aging-like phenotypes including 
growth retardation and skin abnormalities [82]. On the 
other hand, BRCA1 deficiency leads to increase 
expression of several insulin-like growth factor (IGF) 
signalling axis members including IGF-I [83-86], a 
crucial target of the systemic effects of metformin [43, 
71]. BRCA1 appears to directly recapitulate the AMPK-
related anti-lipogenic effects of metformin (which 
rapidly induces inhibitory phosphorylation of Acetyl-
CoA Carboxylase [ACACA] –the first committed 
molecule in the endogenous pathway of fatty acid 
biosynthesis-) because specific sequences of BRCA1 
have been found to interact with and stabilize the 
phosphorylated form of ACACA, thus interfering with 
ACACA lipogenic activity by preventing ACACA 
dephosphorylation [87,88]. Because BRCA1 selectively 
inhibits aromatase expression and thus local, pro-
tumorigenic estrogen production in breast adipose 
fibroblasts, breast adipose stromal cells and breast 
malignant epithelial cells [89-91], metformin’s ability to 
concurrently inhibit IGF-1, endogenous lipogenesis and 
aromatase expression [92-94] must be carefully 
evaluated on its impact against the “endocrine-
genotoxic liberation” [86] that occurs upon transfer 
from the wild-type to the mutant BRCA1 [86,95]. 
Further studies are warranted to evaluate if metformin 
treatment significantly modifies cancer risk due to 
deleterious BRCA1 gene mutations to decrease middle-
age women mortality and/or late-onset familial cancer.  
 
3. Metformin and the senescent phenotype 
 
3.1. Less (accumulation of senescent cells) is More 
(activity of the immune system) 
Anisimov and colleagues studied markers of cellular 
senescence in fibroblasts from skin of SHR mice treated 
with metformin since the 3rd and the 9th months of life 
[43]. Although no direct evidence is provided, the 
authors discuss the possibility that metformin treatment 
may actively prevent accumulation of senescent (“old”) 
cells. We should acknowledge that no hallmark of 
senescence thus far is entirely specific to the senescent 
state and that not all senescent cells express all possible 
senescence markers. Senescent cells, however, display 
several   phenotypes   that,   altogether,   can  define  the  
senescent state as recently reviewed by Rodier & 
Campisi [96]: 1.) Essentially irreversible growth arrest; 
2.) significant increase in size; 3.) expression of 
senescence-associated  -galatosidase (SA-gal; [97]) 
which reflects, at least in part, the increase in lysosomal 
mass [98]); 4.) expression of the tumor suppressor 
p16INK4a, which silences critical pro-proliferative 
genes by causing formation of senescence-associated 
heterochromatin foci (SAHF); 5.) persistent nuclear foci 
termed DNA segments with chromatin alterations 
reinforcing senescence (DNA-SCARS), which contain 
activated DNA damage response (DDR) proteins and 
include dysfunctional telomeres or telomere 
dysfunction-induced foci (TIF); and 6.) robust secretion 
of numerous growth factors, cytokines, proteases and 
other proteins that exhibit potent autocrine and 
paracrine activities (i.e. the senescence-associated 
secretory phenotype [SASP]). When some of theses 
hallmarks of senescent cells were qualitatively assessed 
in skin fibroblasts from SHR mice, metformin treatment 
was found to reduce the number of SAHF foci, the 
average nuclei area, and the nuclei accumulation of 
γH2AX compared to untreated control skin fibroblasts 
[99]. In addition, metformin treatment quantitatively 
reduced the number of fibroblasts with large nuclei area 
as well as the number of fibroblasts positive for SA-
gal activity and positive for intense nuclear γH2AX 
staining [99]. Because short-term dietary restriction 
has recently been shown to decrease abundance of 
senescent cells as assessed by assaying PCNA (as an 
indicator of DNA replication), γH2AX (as an indicator 
of DNA damage) and SA-gal in the liver and 
intestine of middle-aged mice [100,101], and because 
γH2AX is a marker of mTOR-dependent cellular 
senescence in the absence of DNA damage and 
pharmacological blockade of mTOR activity with 
rapamycin efficiently decreases nuclear accumulation 
of  γH2AX in senescent cells [102], it might be 
tempting to speculate that reduced cellular senescence 
might be a primary effect of metformin and, therefore, 
a causal, mTOR-regulated mechanism underlying 
metformin-increased lifespan in female SHR mice. If 
metformin treatment can function in a CR-like manner 
to actively prevent age-related accumulation of 
senescent cells and similar mechanism may apply to 
humans, it should be expected CR to increase the 
number of functional skin fibroblasts. We should 
acknowledge, however, that proliferation-competent 
skin fibroblasts did not increase after 9 to 12 years of 
CR in rhesus monkeys [103]. Nevertheless, it would be 
interesting to determine the impact of metformin 
treatment on the proportion of senescent cells in other 
tissues exquisitely sensitive to the structural and 
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106]).  
 
As mentioned above, one of the hallmarks of senescent 
cells is that the senescence growth arrest is essentially 
permanent and cannot be reversed by known 
physiological stimuli [96]. Therefore, metformin’s 
ability to reduce the decrease senescent cell abundance 
as a function of total cell number may be understood 
mostly in terms of metformin-enhanced clearance of 
senescent cells by the immune system. Although it 
cannot be excluded that metformin treatment may 
actively inhibit production of new senescent cells (thus 
decreasing their “normal” frequency of accumulation in 
aging tissues) the fact that senescent cells are turned 
over slowly strongly suggests that metformin may 
enhance immune system responsiveness to senescent 
cells (thus increasing their “normal” clearance rate in 
aging tissues). If metformin treatment can restore tissue 
health by actively & selectively removing senescent 
cells in aging tissues via activation of the immune 
system, it can be expected that metformin-based 
interventions could delay age-related onset of chronic 
diseases more efficiently if started early in life because 
senescent cells’ ability to induce macrophages declines 
with aging [104]. Anisimov’s findings might support a 
metformin-triggered immunostimulatory-centered 
mechanism that may reduce age-related consequences 
of tissue inflammation due to senescent cell 
accumulation. But, do we have any evidence that 
metformin treatment promotes activation of the immune 
system? Long term CR has long been recognized to 
prevent the age-associated decrease in T-cell 
proliferative capacity in mice [107]. In nonhuman 
primates, CR has been found to similarly promote a 
significant improvement not only in the maintenance 
and/or production of naïve T cells but also in T cell 
function and reduced production of inflammatory 
cytokines by memory T cells [108]. More importantly, 
recent landmark studies have revealed that: a.) the 
metformin target mTOR is a major regulator of memory 
CD8 T-cell differentiation; b.) rapamycin has 
immunostimulatory effects on the generation of 
memory CD8 T cells, and c.) metformin itself enhances 
CD8 T-cell memory. Indeed, metformin-induced 
alteration in fatty acid metabolism during development 
of memory CD8 T cells has been found to considerable 
improve the efficacy of an anti-cancer vaccine [109-
111]. Noteworthy, CD8 T cells, normally considered a 
part of adaptive immunity, also actively participate in 
innate immune responses.   
 
3.2. Less (senescence bystander effect) is More (cancer 
progression-free interval) 
Pioneeringly revealed by current Anisimov’s studies, a 
previously unrecognized ability of metformin to 
regulate the senescent phenotype in vivo may provide 
crucial insights to definitely distinguish a/the 
molecular mechanisms underlying metformin-
promoted anti-aging and/or anti-cancer effects. On the 
one hand, studies of human tissues and cancer-prone 
mice argue strongly that cellular senescence 
suppresses cancer in vivo [112-114]. Senescent cells 
can be found abundantly in intraepithelial pre-
malignant lesions whereas senescent cells are scarce in 
invasive, life-threatening carcinomas. Dismantling the 
senescence response (e.g. by inactivating p53) causes a 
significant acceleration in the development of human 
tumors whereas the senescence response in established 
malignant states is associated with tumor regression. 
In this regard, the regressing tumor elicits an 
inflammatory response that stimulates the innate 
immune system, which eliminates the senescent cells. 
That is, an equivalent mechanism to the one proposed 
for metformin-induced clearance of senescent cells in 
the skin of female SHR mice. Age-related increases in 
senescent cells occur in mitotically competent tissues, 
which are those that give rise to cancer. Moreover, 
senescent cells have been shown to promote malignant 
progression of pre-malignant epithelial cells –which 
do not ordinarily form tumors- as well as established 
cancer cells in in vivo animal models [115-117]. 
Because many SASP proteins can alter epithelial cell 
differentiation, proliferation, migration & invasion 
(e.g. growth factors such as amphiregulin, cytokines 
such as IL-6/IL-8, VEGF, matrix metalloproteinases), 
a probable mechanism through which senescent cells 
can stimulate tumorigenesis in vivo is the bystander 
effect of senescent fibroblasts in the adjacent pre-
malignant/malignant cells [96]. A critical test for the 
idea that senescent cells can promote the progression 
of age-related cancers might require strategies aimed 
to eliminate senescent cells or bystander effects of the 
SASP in vivo. Anisimov’s findings (i.e. metformin 
treatment started early in life significantly postponed 
tumor formation in female SHR mice) appear to agree 
with the idea that metformin’s ability to impair the 
genesis of senescent cells (by decreasing their 
generation, enhancing their elimination, or both) 
negatively impacts the progression of age-related 
cancers. Currently ongoing experiments in our 
laboratory aim to evaluate whether chronic exposure 
of non-transformed human fibroblasts to metformin 
significantly regulates replicative cellular senescence 
via prevention of proliferative exhaustion. Using 
cultured premalignant epithelial cells, we are 
evaluating also whether metformin treatment can 
prevent the hallmarks of malignancy EMT & 
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media originated from senescent fibroblasts.  
 
3.3. Less (threshold for stress-induced senescence) is 
More (elimination of oncogenically primed cells) 
An unexplored scenario relates to metformin’s ability to 
induce and/or enhance senescence responses in tumor 
cells themselves. Senescence-inducing stressors such as 
oxidative damage, DNA damage and/or oncogenes 
normally reach sufficient intensity to trigger senescence 
at the pre-malignant tumor stage. In agreement with a 
role of senescence in cancer prevention, the subsequent 
invasive progression of pre-malignant lesions almost 
inevitably involves one or more events that inhibit or 
impair the senescence pathway (e.g. convergence of 
EMT-driven acquisition of stem cell traits with 
enhanced autophagy in response to bioenergetic stress 
may turn pre-malignant phenotypes into cancer-
initiating cells that efficiently couple invasive/ 
metastatic spread to the bypass of metabolic stress- and 
oncogene-induced cellular senescence [63, 64]). 
Proliferative invasive cancer cells with activated 
oncogenes truly represent progeny of tumor cells that 
have acquired instrumental mechanisms to suppress 
senescence in earlier stages of cancer pathogenesis (e.g. 
in situ lesions). Therefore, activating the program of 
senescence in tumor cells seems an attractive approach 
to cancer treatment [118,119] and may help to 
molecularly explain the differential impact of 
metformin on aging and/or cancer in non-prone and 
cancer-prone animal models. We know that organisms 
in which cells fail to undergo senescence to not live 
longer; rather, they die prematurely of cancer [120]. 
Therefore, metformin treatment does not appear to 
impact aging and/or cancer by preventing general 
cellular senescence, which is rather necessary to 
communicate cellular damage/dysfunction to the 
surrounding tissue and stimulate repair, if needed. A 
normal senescence response helps to resolve fibrotic 
scars after acute liver injury whereas a compromised 
senescence response allows the occurrence of excessive, 
severe fibrosis [121-123]. Accordingly, excessive 
fibrosis due to a sustained, unresolved EMT-related 
synthesis of collagen and extracellular matrix synthesis 
can be found in many age-related human diseases such 
as chronic renal disease, non-alcoholic steatohepatitis, 
heart failure or sclerosis. Of note, we recently revealed 
the anti-fibrotic activity of metformin by using TGF-
induced EMT in Madin-Darby canine kidney (MDCK) 
type I epithelial cells as an in vitro system to study the 
critical involvement of the EMT phenomenon in organ 
fibrosis [37]. Alternatively, metformin might be 
expected to block an essential senescence escape 
mechanism while nullifying EMT-driven CSC features 
by preventing molecular transition of epithelial tumour 
cells to embryonic mesenchymal phenotypes (i.e. EMT) 
[35-38]. Moreover, it may be relevant to evaluate 
whether metformin-altered cancer risk and improved 
health of laboratory animals may relate to its ability to 
activate DNA damage-like signaling to induce specific 
senescence-like growth inhibition of premalignant or 
malignant cells without altering normal breast structures 
or other non-neoplasic tissues. How?  
 
Landmark studies of Lin et al [124] and Campaner et al 
[125] have recently found that the inhibition of the 
activity of cyclin dependent kinases (CDKs) plays a 
significant role in establishing protective cellular 
senescence; particularly, inhibition of CDK2 activity 
appears to be critical to lower the bar for triggering 
senescence in tumor cells [126]. Senescence-inducing 
stressors can inhibit CDK2 activity by either enhancing 
the expression of CDK2 inhibitory proteins (e.g. CDK 
inhibitory kinases or CKIs including p21Waf1/Cip1 and 
p27Kip1) or by inhibiting the expression of CDKi 
inhibitors such as Skp2, a component of the E3 
ubiquitin ligase that mediates ubiquitin-dependent 
degradation of CKIs such as p27Kip1 (thus inhibiting 
CDK2 activity); in this CDK2/Skp2-inhibited scenario, 
oncogenically primed cells can be targeted by 
senescence early on or before reaching pre-tumoral or 
pre-malignant stages as occurs normally. Could 
metformin treatment “encourage cancer-prone cells to 
senesce” [126]? Although direct evidence for its 
occurrence is lacking, metformin may intriguingly 
function as a bona fide senescence-inducing stressor in 
cancer-prone cells when considering that: a.) 
metformin’s inhibitory effects on tumor cell growth 
requires sufficient levels of CDKis (p21Waf1/Cip1 or 
p27Kip1) to bind and inhibit CDK2 [127]; b.) 
pharmacological and small inhibitory RNA-targeted 
ablation of FASN lipogenic activity –a well recognized 
metformin’s molecular target- causes a dramatic down-
regulation of Skp2 [128] to promote a prominent 
accumulation of p27Kip1 [128, 129]. Indeed, it might 
not be necessary for metformin to directly induce 
senescence in oncogenically primed cells. As reported 
by Lin et al [124], Skp2 inactivation on its own failed to 
induce cellular senescence; however, aberrant proto-
oncogenic signals as well as inactivation of tumor 
suppressor genes triggered a potent, tumor-suppressive 
senescence response in mice and cells devoid of Skp2. 
It would be relevant to evaluate whether metformin co-
exposure may favour the “accelerated senescence” 
triggered in normal cells by the expression of mutant 
Ras or Raf (oncogene-induced senescence) and by some 
other forms of supraphysiological mitogenic signaling 
[130-132] getting stuck irrespective of senescence-
inhibiting adaptations (e.g. inactivation of p53). 
Because activation of a persistent DNA damage 
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senescence growth arrest, is a crucial anti-cancer barrier 
in early human tumorigenesis [133, 134], it would be 
very informative to test if metformin can significantly 
increase senescence cell abundance in premalignant 
lesions of the skin, the lung, and the pancreas [135]. 
Because epithelial cells within pre-malignant breast 
lesions that demonstrate markers of senescence and 
maintain an intact response to cellular stress identify 
women that are less likely to develop subsequent tumor 
events (i.e. the pro-senescent mechanisms of the 
Retinoblastoma (RB)/p16INK4a pathways are the most 
accurate predictors of recurrence and DCIS progression 
to EMT-enriched invasive basal-like breast carcinomas 
[136]), a molecular framework for “pro-senescence” 
metformin-based therapy would be evaluated in DCIS 
xenografts before and during in situ to invasive breast 
cancer transition [137-139]. Finally, because many 
tumor cells retain the ability to senesce, in culture and 
in vivo, in response to DNA-damaging 
chemotherapeutic agents [140-142], it might be 
tempting to suggest that metformin-enhanced cellular 
senescence in the context of DDR could explain 
metformin’s ability to increase the rate of pathological 
complete responses to neoadjuvant chemotherapy in 
diabetic patients with breast cancer [143] and to 
promote tumor regression and prevent relapse when 
combined with sub-optimal doses of chemotherapy in 
animal models [144].  
 
3.4. Less (cellular senescence-driven aging-like 
phenotypes) is More (retardation of premature aging) 
Cellular senescence can drive are-related pathologies 
other than cancer. If metformin reduced abundance of 
senescent cells is central to metformin’s ability to 
actively regulate lifespan extension, it would be 
interesting to test if metformin treatment may decelerate 
rapid accumulation of senescent cells and/or the rapid 
development of age-related phenotypes including 
growth retardation, loss of weight, lipodystrophy (i.e. 
loss of adiposity), hair loss and bone density defects. A 
mouse model of Hutchinson-Gilford progeria syndrome 
(HGPS; a childhood premature aging syndrome caused 
by the accumulation at the nuclear envelop of 
farnesylated forms of truncated prelamin A –a protein 
that is also altered during normal aging-) can be 
extremely informative because it develops phenotypes 
that overlap with those of HGPS children and do not 
include cancer even when causing a significant 
alteration in the number and proliferative capacity of 
epidermal stem cells [145, 146]. Administration of 
drugs interfering with the mevalonate pathway such as 
statins and aminobisphosphonates has been found to 
reduce DDR signaling in HGPS cells and to alleviate 
some of the progeroid symptoms in the HGPS mice 
[147]. Of note, in addition to ACACA, metformin’s 
primary target AMPK has been shown to phosphorylate 
and thus regulate the activity of HMG-CoA reductase 
[148]. Metformin-induced activation of AMPK, like 
statins, can be expected to inhibit HMG-CoA reductase 
and suppress the production of downstream metabolites 
including dolichol and isoprenylated GTP-binding 
proteins. Indeed, metformin has been long recognized to 
inhibit cholesterol synthesis in diabetic rats and cultured 
fibroblasts via blockade of HMG-CoA reductase 
activity [149, 150]. It might be very instructive to 
evaluate whether metformin can replace statins and/or 
aminobisphosphonates in preventing aging-like 
phenotypes in animal models of HGPS, particularly 
because premature aging in mice involves a CR-like 
metabolic response molecularly equivalent to that 
occurring in situations reported to prolong lifespan. 
Thus, murine models of human HGPS exhibit an 
extensive basal activation of autophagy associated with 
a series of changes in lipid and glucose metabolic 
pathways leading to peripheral AMPK activation and 
mTOR inhibition [4, 5]. In the meantime, our laboratory 
is currently evaluating whether rapidly decreased 
growth-rate & premature entry into senescence of 
cultured HGPS fibroblasts is preventable by exogenous 
supplementation with metformin.  
 
The key question that remains to be answered in 
Anisimov’s studies relates to the molecular 
mechanism(s) through which metformin treatment 
increased lifespan and delayed tumor formation in 
female SHR mice. An ever-growing experimental body 
of evidence strongly suggests that metformin, at the 
cellular level, works as an efficient deactivator of the 
mTOR/S6K1gerogenetic pathway owing its ability to 
activate the metabolic rheostat AMPK [31]. Although 
we can speculate that metformin-imposed suppression 
of signaling through mTOR and S6K1 is the pivotal 
molecular event underlying metformin-induced 
promotion of longer lifespan & healthier aging, this 
possibility needs to be tested directly in future studies. 
What is obvious is that, if started early in life, chronic, 
sub-clinical doses of the putative mTOR/S6K1 
deactivator metformin efficiently over-ride and take 
control over cell growth factors (gero-promoting) 
signaling to prevent aging-related tissue degeneration 
(e.g. metformin reduced abundance of senescent cells in 
the skin tissue) while improving reproductive function 
(e.g. metformin postponed age-related switch-off of the 
estrous cycle). Metformin’s ability to prevent 
reproductive aging while increasing lifespan, if both 
occurring through AMPK activation-mTOR/S6K1 
deactivation, appears to largely agree with a 
gerosuppressive functioning of metformin (i.e. 
gerosuppressants are pharmacological agents that 
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drive cellular aging and thus suppress the aging process 
[151,152]). Gerosuppressant metformin cannot 
distinguish between mTOR-driven program (which 
drives growth, fitness and the onset of reproduction 
early in life) and quasi-program (which causes 
menopauses, diseases such as cancer and aging later in 
life, when the mTOR-driven program becomes aimless) 
[151-153]. It is tempting to suggest that chronic 
exposure to sub-clinical doses of metformin institutes 
an autonomously-driven feedback regulatory loop of 
intermediary metabolism which ignores numerous & 
tissue-specific gero-promoting signaling to such a 
degree that it can significantly extend lifespan and 
postpone tumor formation. If we knew of any similar 
feedback inhibitor of mTOR that prevents age-related 
pathologies, analogies might then be helpful. Recent 
studies have revealed that sestrins –an ancient family of 
conserved oxidative proteins that accumulate in cells 
exposed to stress- activate AMPK and inhibit activation 
of mTOR. More importantly, sestrins appear to function 
as a negative feedback regulator of mTOR that 
integrates metabolic and stress inputs and prevents 
gero-pathologies caused by chronic activation of 
mTOR. Indeed, pharmacological activation of AMPK 
or inhibition of mTOR prevented age-associated 
pathologies induced by loss of sestrins [154-157]. In 
response to damaged mitochondrial production of 
reactive oxygen species (ROS), sestrin is upregulated to 
activate AMPK which in turn, inhibits mTOR to 
downregulate anabolism and promote mitochondrial 
biogenesis, thus decreasing ROS to feedback inhibiting 
sestrin. In response to metformin bound complex I of 
the respiratory chain electron transfer is inhibited and 
increases the levels of ROS [158]; inhibition of complex 
I would cause a decrease in energy supply that would in 
turn lead to a higher AMP/ATP ratio, and the 
concomitant activation of AMPK accompanied by 
downstream inhibition of mTOR; metformin-induced 
activation of AMPK increases the expression of 
peroxisome proliferator-activated response-gamma 
coactivator-1alpha (PGC-1alpha) and mitochondrial 
biogenesis [159, 160]. Metformin, as sestrins, can 
simultaneously function as ROS feedback homeostasis 
control system and as inhibitor of mTOR. As 
auspiciously suggested by Topisirovic & Sonemberg 
“as sestrins appear to amend the age-related effects of 
excessive TOR signaling, developing molecular mimics 
of sestrin could open new therapeutic avenues to target 
age-related pathologies” [155]. Results of forthcoming 
molecular biological studies should definitely establish 
if metformin is a “sestrin-mimic” molecule that 
clinically merits to be repositioned from type 2 diabetes 
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